Traditionally, buprenorphine is described as a partial MOR agonist that is known for limited analgesic effects and developed with the intent for a limited potential for respiratory depression and addiction [15]. The gene discussed is OPRM1; the disease is Respiratory insufficiency due to muscle weakness.